Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP2AXV)

• Drug Name: Imidazopyridine derivative 4 Drug Info
• Synonyms: PMID27774824-Compound-Figure12Example14
• Cross-matching ID: TTD Drug ID: DMP2AXV

Molecule-Related Drug Atlas

Drug(s) Targeting Janus kinase 3 (JAK-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[2]
Ritlecitinib	DMYKNME	Alopecia areata	ED70.2	Approved	[3]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[4]
VX-509	DM2U3MX	Rheumatoid arthritis	FA20	Phase 2/3	[5]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[3]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[6]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[7]
TD-8236	DMTOMJN	Asthma	CA23	Phase 2	[8]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[9]
SNA-125	DM8L1GJ	Atopic dermatitis	EA80	Phase 1	[3]

Drug(s) Targeting Tyrosine-protein kinase BTK (ATK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibrutinib	DMHZCPO	Mantle cell lymphoma	2A85.5	Approved	[10]
Acalabrutinib	DM7GCVW	leukaemia	2A60-2B33	Approved	[11]
Zanubrutinib	DMJWRQP	Mantle cell lymphoma	2A85.5	Approved	[12]
Pirtobrutinib	DMRG1X3	Non-hodgkin lymphoma	2B33.5	Approved	[13]
GDC-0853	DMBEL3Q	Multiple sclerosis	8A40	Phase 3	[14]
ICP-022	DMU72KL	Chronic lymphocytic leukaemia	2A82.0	Phase 3	[15]
Tolebrutinib	DML19V6	Multiple sclerosis	8A40	Phase 3	[16]
CC-292	DMJR9H0	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[17]
BMS-986142	DMZB8AJ	Rheumatoid arthritis	FA20	Phase 2	[14]
LOU064	DME8O5K	Chronic idiopathic urticaria	EB00.1	Phase 2	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 3 (JAK-3)	TTT7PJU	JAK3_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[1]

References

• [1] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
• [5] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [6] Clinical pipeline report, company report or official report of Aclaris Therapeutics.
• [7] ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [9] The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
• [11] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [13] Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of InnoCare Pharma.
• [16] Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738.
• [17] Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.